Rosalía Caballero

3.9k total citations
42 papers, 1.2k citations indexed

About

Rosalía Caballero is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rosalía Caballero has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Rosalía Caballero's work include Advanced Breast Cancer Therapies (15 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (11 papers). Rosalía Caballero is often cited by papers focused on Advanced Breast Cancer Therapies (15 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (11 papers). Rosalía Caballero collaborates with scholars based in Spain, United States and Canada. Rosalía Caballero's co-authors include Eva Carrasco, Miguel Martín, Philip S. Bernard, Aleix Prat, Charles M. Perou, Joel S. Parker, Scott Tyldesley, Maggie C.U. Cheang, Karen A. Gelmon and Torsten O. Nielsen and has published in prestigious journals such as Journal of Biological Chemistry, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Rosalía Caballero

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rosalía Caballero Spain	14	639	599	454	178	157	42	1.2k
Sergio Aguggini Italy	17	665 1.0×	709 1.2×	470 1.0×	159 0.9×	141 0.9×	34	1.3k
Giovanni Allevi Italy	17	603 0.9×	669 1.1×	437 1.0×	150 0.8×	136 0.9×	36	1.2k
Aiko Sueta Japan	18	340 0.5×	487 0.8×	455 1.0×	157 0.9×	185 1.2×	45	947
Yasuyo Ohi Japan	21	635 1.0×	474 0.8×	314 0.7×	123 0.7×	177 1.1×	60	1.2k
Hans Halfwerk Netherlands	15	525 0.8×	787 1.3×	553 1.2×	122 0.7×	158 1.0×	19	1.2k
Alessandra Bersiga Italy	16	641 1.0×	658 1.1×	458 1.0×	146 0.8×	124 0.8×	31	1.2k
Anne‐Lise Børresen‐Dale Norway	15	446 0.7×	527 0.9×	822 1.8×	210 1.2×	123 0.8×	20	1.2k
Mutsuko Yamamoto‐Ibusuki Japan	20	445 0.7×	509 0.8×	553 1.2×	158 0.9×	250 1.6×	45	1.1k
Tarek M.A. Abdel-Fatah United Kingdom	19	549 0.9×	350 0.6×	767 1.7×	109 0.6×	98 0.6×	34	1.1k
Jarle B. Arnes Norway	18	431 0.7×	418 0.7×	567 1.2×	106 0.6×	125 0.8×	28	1.0k

Countries citing papers authored by Rosalía Caballero

Since Specialization

Citations

This map shows the geographic impact of Rosalía Caballero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosalía Caballero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosalía Caballero more than expected).

Fields of papers citing papers by Rosalía Caballero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosalía Caballero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosalía Caballero. The network helps show where Rosalía Caballero may publish in the future.

Co-authorship network of co-authors of Rosalía Caballero

This figure shows the co-authorship network connecting the top 25 collaborators of Rosalía Caballero. A scholar is included among the top collaborators of Rosalía Caballero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosalía Caballero. Rosalía Caballero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taylor, Clive R., Carlos H. Barrios, Manuel Ruíz-Borrego, et al.. (2024). Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial.. Journal of Clinical Oncology. 42(16_suppl). 516–516. 1 indexed citations

Albanell, Joan, María Teresa Martínez, Miriam O’Connor, et al.. (2024). Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.. Journal of Clinical Oncology. 42(16_suppl). 1028–1028.

Ocaña, Alberto, Marta Gil-Martín, Silvia Antolín, et al.. (2019). Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment. 174(3). 693–701. 36 indexed citations

Quiroga, Vanesa, Esther Holgado, José Luis Alonso-Romero, et al.. (2018). Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Annals of Oncology. 29. x32–x32. 1 indexed citations

Ruíz‐Borrego, Manuel, Begoña Jiménez, Silvia Antolín, et al.. (2018). A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study. Investigational New Drugs. 37(1). 98–108. 50 indexed citations

Templeton, Arnoud J., Álvaro Rodríguez-Lescure, A. Ruíz, et al.. (2018). Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology. 20(12). 1548–1556. 10 indexed citations

Borrego, Manuel Ruíz, Marta Gil-Martín, Silvia Antolín, et al.. (2017). A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Annals of Oncology. 28. v75–v75. 1 indexed citations

Martín, Miguel, Jan C. Brase, Amparo Ruı́z, et al.. (2016). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment. 156(1). 81–89. 35 indexed citations

Ethier, Josée-Lyne, Alberto Ocaña, Maribel Casas, et al.. (2016). Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology. 34(15_suppl). 569–569. 3 indexed citations

10.

Ocaña, Alberto, Arnoud J. Templeton, María Isabel Casas, et al.. (2016). Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer. Annals of Oncology. 27. vi43–vi43. 1 indexed citations

11.

Santonja, Ángela, Joan Albanell, Alfonso Sánchez‐Muñoz, et al.. (2016). Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer. Annals of Oncology. 27. vi55–vi55.

12.

Cruz‐Merino, Luis de la, et al.. (2016). Breast Cancer Immunology and Immunotherapy. International review of cell and molecular biology. 331. 1–53. 44 indexed citations

13.

Alba, Emilio, Joan Albanell, Juan de la Haba-Rodríguez, et al.. (2014). Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. 110(5). 1139–1147. 55 indexed citations

14.

Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38. 107 indexed citations

15.

Rojo, Federico, Aňa Lluch, Amparo Ruı́z, et al.. (2014). Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology. 32(15_suppl). 11107–11107. 1 indexed citations

16.

Prat, Aleix, Maggie C.U. Cheang, Miguel Martín, et al.. (2012). 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer. Annals of Oncology. 23. ii17–ii18. 4 indexed citations

17.

Ebbert, Mark, Roy R. L. Bastien, Kenneth M. Boucher, et al.. (2011). Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. PubMed. 1(1). 37–37. 12 indexed citations

18.

Ropero, Santiago, Mario F. Fraga, Esteban Ballestar, et al.. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics. 38(5). 566–569. 206 indexed citations

19.

Boix-Chornet, Manuel, Mario F. Fraga, Ana Villar‐Garea, et al.. (2006). Release of Hypoacetylated and Trimethylated Histone H4 Is an Epigenetic Marker of Early Apoptosis. Journal of Biological Chemistry. 281(19). 13540–13547. 30 indexed citations

20.

Morato, T, et al.. (1972). [Half-life of blood cortisol in normal subjects].. PubMed. 22(4). 355–63. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact